Key Drivers
- Improving margins
- Low FCF
- Heavy capex
AIAI Summary
Stevanato is shifting from low‑margin packaging toward higher‑value biologics and drug‑delivery products that can materially re-rate the stock, but investors are effectively funding that upside today amid heavy, front‑loaded capex and margin‑dilutive site ramps. Watch for specific execution triggers — positive gross‑margin turnarounds at Fishers/Latina, a clear FCF inflection (meaningful capex taper or sustained positive FCF), and normalized working‑capital conversion across two consecutive quarters — before upgrading the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving margins
- •Low FCF
- •Heavy capex
STVN exhibits improving margins, solid liquidity and moderate leverage but generates very low free cash flow due to heavy capex and faces a rich market valuation.
Price Behavior
Key Price Behavior Insights:
- •Below last-month MA
- •At multi-session low
- •Near $15.9/$17.5 resistance
STVN is mildly bearish—trading below its last-month moving average (~$15.41) and at multi-session lows near $14.60–$14.99, with resistance around $15.90 and $17.50; a decisive break below the $14.60–$14.99 area would signal increased downside risk.
Clear decline from the mid‑January peaks (~$21.90–$19.80) into
Sentiment & News
Key News Insights:
- •GLP‑1 demand
- •Capex focus
- •Mixed sentiment
Stevanato Group posted FY2025 revenue and margin gains led by high‑value biopharma/GLP‑1 products and beat Q4 estimates, but heavy capex, weak Engineering sales and a Citigroup price‑target cut sparked mixed analyst/investor reactions and an 8.5% share drop.
Product-driven revenue and margin momentum supports future earnings upside, but capex intensity and division weaknesses leave the stock vulnerable to further sentiment-driven volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings